EFDA Structure, Functions and Regulatory Scope for Medical Devices

1. Key takeaways

The Ethiopian Food and Drug Authority (EFDA) is the federal competent authority for regulated products, and its medical devices directorate is organized internally into three functional blocks: inspection and enforcement for medical device manufacturers, quality control, and registration and marketing authorization. Almost every question a company encounters in Ethiopia can be mapped onto one of these three blocks, and identifying the correct counterpart early saves weeks of correspondence. Sending a question to the wrong unit is one of the main reasons why inquiries go unanswered for long periods. Companies should also remember that EFDA operates alongside regional and city administration regulatory bodies, so the level of government that handles a specific matter — a facility inspection, a storage-site question, a distribution complaint — is not always the federal headquarters. Finally, vigilance and post-market surveillance have their own dedicated desk and reporting channels, separate from the registration units. Building a simple mapping of issue type to responsible unit, and routing all external communication through the local agent, is the most effective way to keep Ethiopian regulatory interactions moving.

2. Legal basis

3. Expert insights

Insight 1: the division among registration, quality and inspection determines the handling path of every issue. Dossier content and technical queries belong to registration and marketing authorization; laboratory testing and quality disputes belong to quality control; premises violations, counterfeit products and conduct-of-trade matters belong to inspection and enforcement. Sending a technical query to the enforcement unit, or a complaint to the registration unit, measurably extends processing time because the material must be re-routed internally before anyone can act on it.

Insight 2: EFDA’s stated position on foreign manufacturers makes the local agent irreplaceable. Section 7.5 of the general guideline states clearly that EFDA has neither the mandate nor the intention to register foreign medical device manufacturers; its basic means of regulatory control is to collect and retain information on manufacturers, authorized representatives, importers, distributors and wholesalers, together with the devices they supply. This means that an overseas entity has no independent legal identity in Ethiopia, and all obligations must be implemented through the local agent. Every application, response and report is filed in the name of an Ethiopian-established entity.

Insight 3: headquarters and regional regulators operate in parallel, and the place of business affects who inspects. EFDA maintains branches across the country and cooperates with regional and city administration regulatory bodies. When selecting warehouse locations or scheduling facility inspections, companies must confirm which level of authority has competence rather than assuming that everything is handled by the federal headquarters. Aligning the site’s registration and inspection arrangements with the correct level avoids duplicated communication and conflicting findings.

Insight 4: vigilance and post-market surveillance have dedicated counterparts. The Medical Device Vigilance & PMS desk receives adverse event reports, and a dedicated e-mail address is provided for submitting report forms. Sending a vigilance report to the registration unit may fail to satisfy the formal requirements of the applicable timelines, since the clock and the receipt are established through the designated channel. Companies should document each transmission with proof of sending to evidence timely compliance.

Insight 5: EFDA’s scope of powers has been narrowed to products and related establishments. Following Regulation No. 531/2023, the regulatory scope moved from products, professionals, premises and practices to regulated products and the establishments related to them. When judging whether a particular licence is still issued by EFDA, companies must verify against the post-regulation understanding, because some authorizations previously associated with the authority now fall under other bodies or levels of government.

4. Practical recommendations

1. Select the counterpart unit by issue type: registration, quality and enforcement are three separate lines of contact.
2. Route all external communication through the local agent: overseas entities have no independent filing identity.
3. Submit vigilance reports through the dedicated channel and retain proof of sending to evidence timeline compliance.
4. Confirm the competent level of authority before choosing premises or warehouse sites to avoid mismatches at inspection.
5. Build an issue-to-unit mapping table and share it with the whole regulatory team to reduce back-and-forth.
6. Cite statutory provisions in major disputes to raise the level and persuasiveness of communication.

5. Verification checklist

• □ Confirmed the counterpart unit by issue type (registration / quality / enforcement)
• □ Confirmed that all submissions are filed through the local agent
• □ Recorded the dedicated reporting channel for vigilance and post-market surveillance
• □ Confirmed the level of the competent authority for premises and warehouses
• □ Built an issue-to-unit mapping table and synchronized it within the team

Regulatory information verified as of October 29, 2026. The unit structure, functional division and contact channels listed above are based on the information published by the Ethiopian Food and Drug Authority (EFDA) currently in force; where the organizational structure is adjusted, the information must be re-checked.

• Ethiopia local support: GRZAN assists manufacturers from the Chinese mainland and overseas in dealing with the Ethiopian Food and Drug Authority (EFDA) on marketing authorization (MA), Certificate of Competence (CoC) and import permit applications, including local agent planning and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical dossier preparation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization applications and re-registration, low-risk notification eligibility assessment, Essential Principles conformity justification, labelling and instructions-for-use localization in English, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.